Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
Jedd D. Wolchok, Jeffrey S. Weber, Michele Maio et al. · Annals of Oncology · 2013
Cited by 176 works. doi:10.1093/annonc/mdt161 Open-access PDF
Authors
- Jedd D. Wolchok
- Jeffrey S. Weber
- Michele Maio
- Bart Neyns
- Kaan Harmankaya
- Kevin M. Chin
- Lori Cykowski
- Veerle de Pril
- Rachel W. Humphrey
- Célèste Lebbé
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Final Version of 2009 AJCC Melanoma Staging and Classification
- A Confidence Interval for the Median Survival Time
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment